BiologIC Technologies

Blockbuster Medicine or Blockbuster Video? Software will eat the world of advanced therapy. This will create new winner takes all markets and dematerialise others. Successful modern biotechs will take advantage of key strategic trends: 1. Democratisation of capabilities that used to be expensive, artisan and siloed. Any startup can move faster and capture vastly greater value now by building their own manufacturing from day one. 2. Convergence of domains that used to be separate. Bioprocessing and biomanufacturing are converging into micro, mini and maxi factories providing a common platform for R&D, process development and manufacturing. Winning is now based on agility not capacity. 3. Digitilisation that enables mass customisation of complex yet manufacturable mono- and combi- therapies matched to patients based on scientific advances and personal and population data. Blockbuster Medicines will be more affordable, available, precisely tuned and delivered on demand whenever and wherever needed by patients. Blockbuster Video moments await those that fail to modernise. Thanks to our friends at Life Science Integrates, chair Phil Carvil and eminent co-panellists James FRY, Philip Cruz, Jenny Barnett, Nicola Clear for a great discussion! Talk to us today at info@biologic.tech.com. Follow BiologIC Technologies to hear about the latest advanced bioprocessing systems that improve safety, efficacy and viability. #digitalisation #Bioprocessing #ScalableBiomanufacturing #AdvancedTherapies

It costs you $2m every day your therapy is not on the market. The magic is in achieving product-market fit before you run out of money. But patent clocks tick, R&D costs surge and your markets are lost to competitors who win the first-in-class and best-in-class categories that were yours for the taking. The demand for accelerated process development is clear! But…your days are filled with managing safety, efficacy and now you also have to think about production viability. You are under pressure to select the best candidates avoiding dangerous false positives and negatives, screen for the best reagents, ratios and process parameters to deeply understand the scalability and reproducibility of your process. So how do you balance speed with risk? With precision. You need precision experiments, with precision process control, in precision production micro-environments with precision sensing to capture precision data. Precision builds the scientific evidence base for confident decision making that leads to patient success. Faster development and lower risk? It is possible. With precision. Talk to us today at info@biologic.tech.com. Follow BiologIC Technologies to hear about the latest advanced bioprocessing systems that improve safety, efficacy and viability. #Bioprocessing #SmallScaleBioreactors #AdvancedTherapies

Shake Crunch causes painful safety, efficacy and viability failures for therapy developers...

Precision LNPs: small scale bioreactors in downstream processing While installing a new system at a customer site recently, I reflected on the important role small scale precision bioreactors are now playing in the production of complex vesicles like lipid nanoparticles (LNPs), which are essential to the delivery of mRNA vaccines and gene therapies. LNPs are now established as the backbone of mRNA medicines, and many new biologic modalities are rapidly advancing whose targeted delivery will use established and new chemistries combined with ranges of therapeutic payloads. Small scale precision bioreactors are displacing own-built stirrer setups to help researchers develop better formulations faster. Precision bioreactors must be durable for chemical resistance and configurable in terms of setup. They must provide precise control of mixing dynamics, temperature, titration timing and speeds and other formulation conditions to create consistent, stable, high-quality nanoparticles. Better yet, all of this can be modelled and further understood using Computational Fluid Dynamics. By enabling high-throughput screening of multiple formulations at R&D and production volumes, parallel precision bioreactor arrays also accelerate the journey of LNPs from discovery to in vitro and in vivo data and into clinical trials, ultimately driving forward patient success. Add to that both the production speed and the resource efficiency – less expensive material wasted, lower costs, and better results – and it's clear why modern biotechs are adopting these systems to drive LNP production. Talk to us about either bioreactor-based or microfluidic Precision LNPs today at info@biologic.tech.com. Follow BiologIC Technologies on LinkedIn for more content about the latest advanced bioprocessing systems. #Bioprocessing #LNPs #mRNATherapies #Innovation #SmallScaleBioreactors #AdvancedTherapies

Hi fi twins: scale down models that match your GMP process...

Modern biotechnology enterprises built on precision technology platforms will move faster than ever before to improve human health and our environment. It is our responsibility to share the stories of how society will benefit from the work of our science community and also to inspire tomorrow's bioengineers who will shape the world for the better. Thank you to Janine Machin, Technology Correspondent at BBC News, for broadcasting and writing on our story so eloquently.

Imagine developing advanced medicines on the same end-to-end integrated bioprocessing platform that will both get you to clinic faster and distribute manufacture...and that our technology makes this so affordable that any startup with ambitious science can "Build on BiologIC" and control their own destiny...! Excited to work with the forward-thinking and eminent scientists at CEPI (Coalition for Epidemic Preparedness Innovations) as a part of our rapidly growing bioprocessing ecosystem.

BiologIC has partnered with UK Space Agency to adapt its precision bioprocessing platform to a configuration suitable for microgravity operation in Low Earth Orbit and space environments. Space biomanufacturing will become a strategic imperative for nations needing to sustain human activities in deep space and for biopharmaceutical companies seeking new therapeutic value from microgravity environments. Biocomputer technology promises to meet the exacting demands of extreme environments by providing robust, distributed and semi-autonomous bioprocessing infrastructure that can be reconfigured to a broad range of therapeutic and synthetic biology applications. Addressing applications in cell, gene, antibody, ADC, RNA-LNP and stem cell therapies, biocomputer technology is being rapidly adopted by modern biotechnology enterprises. The proprietary platform architecture outmodes expensive legacy hardware because it is standardised yet configurable, modular and highly integrated giving greater process robustness, flexibility and scalability. The end-to-end integrated platform enables true digitalisation of bioproduction for the age of AI. UKSA is investing £65m in ground-breaking innovations that could boost UK leadership in space technologies and applications through its National Space Innovation Programme to support projects designed by British organisations with the potential to accelerate the development of new space technologies and services. #bioprocessing #biomanufacturing #spacetechnology

BiologIC Technologies and CEPI (Coalition for Epidemic Preparedness Innovations) are collaborating on a precision mRNA-LNP bioprocessing platform to greatly accelerate time to clinic and distribute continuous vaccine manufacturing to the point of need to contain or stop disease outbreaks. Addressing applications in cell, gene, antibody, ADC, RNA-LNP and stem cell therapies, biocomputer technology is being rapidly adopted by modern biotechnology enterprises. The proprietary platform architecture outmodes expensive legacy hardware because it is standardised yet configurable, modular and highly integrated giving greater process robustness, flexibility and scalability. The end-to-end integrated platform enables true digitalisation of bioproduction for the age of AI. CEPI is backed by the Bill & Melinda Gates Foundation. Central to CEPI’s pandemic-beating five-year plan is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. #vaccines #RNAtherapy #bioprocessing